Purpose: 

To quantify changes of the retinal vascular bed area (RVBA) in mm² on stereographically projected ultrawide field fluorescein angiography images in eyes with proliferative diabetic retinopathy after antivascular endothelial growth factor injection.

Methods: 

This is a prospective, observational study. The early-phase ultrawide field fluorescein angiography images (Optos 200Tx) of 40 eyes with proliferative diabetic retinopathy and significant nonperfusion obtained at baseline and after six months (NCT02863354) were stereographically projected by correcting peripheral distortion. The global retinal vasculature on ultrawide field fluorescein angiography was extracted for calculating RVBA by summing the real size (mm²) of all the pixels automatically.

Results: 

For the entire cohort, the global RVBA for the entire retina decreased from 67.1 ± 15.5 to 43.6 ± 18.8 mm² after anti-VEGF treatment at six months (P < 0.001). In the subgroup receiving monthly anti-VEGF injections, the global RVBA decreased from 68.7 ± 16.2 to 33.9 ± 13.3 mm² (P < 0.001). In the subgroup receiving anti-VEGF every three months, the global RVBA decreased from 65.6 ± 15.1 to 50.8 ± 19.3 mm² (P = 0.004).

Conclusion: 

RVBA seems to be a new biomarker to indicate efficiency of retinal vascular changes after anti-VEGF injection. Eyes with proliferative diabetic retinopathy and significant nonperfusion demonstrate reduced RVBA after anti-VEGF treatment.

中文翻译：

---

新的生物标志物量化了增殖性糖尿病视网膜病变眼中抗 VEGF 治疗对超声场荧光血管造影的影响：恢复研究

目的： 

在注射抗血管内皮生长因子后，在患有增殖性糖尿病视网膜病变的眼睛中，在立体投影的超广角荧光素血管造影图像上量化视网膜血管床面积 (RVBA) 的变化（以 mm ^{2为单位）。}

方法： 

这是一项前瞻性、观察性研究。通过校正周边畸变对 40 只患有增殖性糖尿病视网膜病变和显着无灌注的眼睛在基线和六个月后 (NCT02863354) 的早期超广角荧光血管造影图像 (Optos 200Tx) 进行立体投影。通过自动对所有像素的实际尺寸 (mm ² )求和来提取超广角荧光素血管造影中的全局视网膜脉管系统以计算 RVBA 。

结果： 

对于整个队列，抗 VEGF 治疗 6 个月后，整个视网膜的整体 RVBA 从 67.1 ± 15.5 下降到 43.6 ± 18.8 mm ^{2 (} P < 0.001)。在每月接受抗 VEGF 注射的亚组中，整体 RVBA 从 68.7 ± 16.2 下降到 33.9 ± 13.3 mm ² ( P < 0.001)。在每三个月接受抗 VEGF 治疗的亚组中，整体 RVBA 从 65.6 ± 15.1 下降到 50.8 ± 19.3 mm ² ( P = 0.004)。

结论： 

RVBA 似乎是一种新的生物标志物，可表明抗 VEGF 注射后视网膜血管变化的效率。患有增殖性糖尿病视网膜病变和显着无灌注的眼睛在抗 VEGF 治疗后表现出 RVBA 降低。